[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"portal-vein-thrombosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:portal-vein-thrombosis":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,43,78,120,145,163,185,210,229,252,273,296],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100640764","direct-oral-novel-anticoagulants-for-patients-with-high-risk-gastroesophageal-variceal-bleeding-and-portal-vein-thrombosis-100640764",false,"NCT07602062","Direct Oral Novel Anticoagulants for Patients With High-risk Gastroesophageal Variceal Bleeding and Portal Vein Thrombosis","Multicenter Randomized Controlled Clinical Trial on Direct Oral Novel Anticoagulants for Improving the Prognosis of Cirrhotic Patients With High-risk Gastroesophageal Variceal Bleeding and Portal Vein Thrombosis","Inclusion Criteria:\n\n* Clinical and imaging diagnosis of liver cirrhosis and esophagogastric varices, with at least one previous episode of esophagogastric variceal bleeding\n* Combined with portal vein thrombosis and D-dimer \\> 0.8mg\u002FL\n* Endoscopic evaluation reveals a high risk of variceal bleeding, and endoscopic treatment is performed to prevent rebleeding of esophagogastric varices\n* Signed informed consent form\n\nExclusion Criteria:\n\n* Received other antithrombotic therapies before (including warfarin, aspirin, low-molecular-weight heparin, etc.)\n* Combined with hepatocellular carcinoma or other malignancy\n* Combined with portal cavernoma\n* Combined with severe life-threatening diseases of circulatory, hematological and respiratory system\n* Combined with diseases requiring anticoagulant therapy, such as acute portal vein thrombosis, atrial fibrillation, lower extremity venous thrombosis, and pulmonary embolism\n* Received TIPS or liver transplantation or splenectomy\n* With contraindications to anticoagulant therapy (uncontrollable active bleeding, severe hepatic insufficiency, renal insufficiency, etc.)\n* Currently taking immunosuppressive agents, or medications that affect cytochrome P450 (including azole antifungals and protease inhibitors), or strong inducers of CYP3A4 (including rifampicin, phenytoin, carbamazepine, etc.)","ALL","18 Years","75 Years",{"count":20,"type":21},175,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study aims to explore the safety and efficacy of oral administration of a novel anticoagulant (rivaroxaban) in patients with cirrhosis accompanied by high-risk esophagogastric variceal bleeding and portal vein thrombosis, through a prospective, multicenter, randomized controlled clinical trial, starting 48 hours after endoscopic treatment to prevent rebleeding.",[27,28,29],"Portal Vein Thrombosis","Anticoagulant Therapy","Variceal Bleeding","NOT_YET_RECRUITING","2026-05-16",{"date":33,"type":34},"2026-05-22","ACTUAL",{"date":36,"type":21},"2026-06-01",{"date":38,"type":21},"2027-12-31",{"name":40,"class":41},"Shanghai Zhongshan Hospital","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":52,"targetDuration":54,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":63,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":42},"100499384","freiburg-tips-registry-100499384","NCT05782556","Freiburg TIPS Registry","Transjugular Intrahepatic Portosystemic Shunt (TIPS) for the Treatment of Portal Hypertension: an Observational Study","FRETIR","Inclusion Criteria:\n\n* Patients allocated to TIPS implantation due to clinically significant cirrhotic and non-cirrhotic portal hypertension\n\nExclusion Criteria:\n\n* Withdrawal of written informed consent","100 Years",{"count":53,"type":21},2000,"12 Months","OBSERVATIONAL","Patients with clinically significant portal hypertension allocated to implantation of a transjugular intrahepatic portosystemic shunt (TIPS) at the Department of Medicine II of the University Medical Center Freiburg, Germany will be offered to participate in this prospective observational trial.\n\nClinical and laboratory as well as outcome parameters will be assessed before and within the first 12 months after TIPS implantation following a regular follow-up schedule with clinical visits at the University Medical Center Freiburg. During follow-up visits, serum\u002Fplasma samples and peripheral blood mononuclear cells (PBMC) are collected and stored in a associated biobank.",[58,59,60,61,27,62],"Liver Cirrhosis","Portal Hypertension","Non-Cirrhotic Portal Hypertension","Budd Chiari Syndrome","Portal Systemic Shunt",[64,65,60,66,67],"Liver cirhosis","Transjugular intrahepatic portosystemic shunt","Prognosis","Outcome","RECRUITING","2026-04-27",{"date":71,"type":34},"2026-05-01",{"date":73,"type":34},"2023-01-01",{"date":75,"type":21},"2034-06-30",{"name":77,"class":41},"University Hospital Freiburg",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":22,"phases":88,"briefSummary":90,"conditions":91,"keywords":96,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":42},"100633026","phase-4-apixaban-pk-trial-preventing-portal-hypertension-complications-in-cirrhosis-100633026","NCT07521332","Apixaban-PK Trial: Preventing Portal Hypertension Complications in Cirrhosis","Apixaban Plus Carvedilol to Prevent Portal Hypertension Complications in Cirrhosis: A Randomized Single-Blind Placebo-Controlled Trial at AIMS, Hyderabad, Pakistan","APIXABAN-PK","Inclusion Criteria:\n\n1. Adults aged ≥18 years with diagnosed cirrhosis (any etiology), confirmed by histology, transient elastography (≥12.5 kPa), or consistent clinical\u002Fimaging findings.\n2. Evidence of portal hypertension, defined by:\n\n   Clinical: presence of varices on endoscopy, ascites, or splenomegaly with thrombocytopenia.\n3. Compensated or early decompensated cirrhosis (Child-Pugh B 7-10), with stable liver function defined as no change in Child-Pugh score \\>1 point in the preceding 3 months.\n4. Screening esophagogastroduodenoscopy (EGD) performed within 6 months prior to enrollment. Patients with high-risk varices (large varices, red wale signs, or history of variceal bleeding) must undergo endoscopic variceal band ligation to obliteration before randomization.\n5. Able to provide informed consent and comply with study procedures.\n\nExclusion Criteria:\n\n1. Active gastrointestinal bleeding within 6 weeks prior to enrollment.\n2. High bleeding risk:\n\n   * Platelet count \\\u003C50,000\u002FµL at baseline\n   * INR \\>1.8 (or \\>2.0 if secondary to cirrhosis without additional coagulopathy)\n   * Active peptic ulcer disease\n   * History of intracranial hemorrhage or hemorrhagic stroke\n   * Known bleeding diathesis\n3. Severe renal impairment (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m²) or on dialysis.\n4. Child-Pugh class C or Child-Pugh score ≥10.\n5. History of hypersensitivity to apixaban or carvedilol.\n6. Pregnancy, breastfeeding, or unwillingness to use effective contraception during the study period.\n7. Concurrent anticoagulant or antiplatelet therapy (including aspirin, clopidogrel, warfarin, or other DOACs) that cannot be safely discontinued. A washout period of at least 5 half-lives is required before randomization.\n8. Use of NSAIDs, SSRIs, or other medications that significantly increase bleeding risk, unless approved by the PI with clear risk-benefit justification.\n9. Active hepatocellular carcinoma (HCC) outside Milan criteria or with vascular invasion.\n10. Current or planned liver transplantation.",{"count":87,"type":21},220,[89],"PHASE4","The APIXABAN-PK trial is a prospective, randomized, single-blind, placebo-controlled study designed to evaluate the efficacy and safety of apixaban in combination with carvedilol versus placebo with carvedilol in preventing portal hypertension-related complications in patients with cirrhosis. Conducted at the Gastroenterology and Hepatology Department and Clinical Trials Unit (CTU) of Asian Institute of Medical Sciences (AIMS) Hospital, Hyderabad, Pakistan, the trial will enroll eligible cirrhotic patients with portal hypertension. Participants will be followed for 12 months to monitor hepatic decompensation events, variceal bleeding, portal vein thrombosis, and mortality, while safety and tolerability of apixaban will be closely assessed. This study aims to provide local evidence for apixaban use in cirrhosis management in Pakistan.",[92,93,94,95,27,59],"Cirrhosis","Esophageal and Gastric Varices","Ascites","Hepatic Encephalopathy",[97,98,99,100,101,102,103,104,105,106,107,108,109,110],"apixaban","carvedilol","cirrhosis","portal hypertension","direct oral anticoagulant","variceal bleeding","hepatic decompensation","portal vein thrombosis","randomized controlled trial","Pakistan","Factor Xa Inhibitor","non-selective beta-blocker","prevention","liver disease","2026-04-03",{"date":113,"type":34},"2026-04-09",{"date":115,"type":34},"2026-04-01",{"date":117,"type":21},"2028-04-01",{"name":119,"class":41},"Asian Institute Of Medical Sciences",{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":4,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":127,"targetDuration":4,"studyType":22,"phases":129,"briefSummary":130,"conditions":131,"keywords":134,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":141,"leadSponsor":143,"locationsCount":42},"100628431","efficacy-of-apixaban-in-the-treatment-of-portal-vein-thrombosis-occurring-more-than-one-year-after-ls-100628431","NCT07461545","Efficacy of Apixaban in the Treatment of Portal Vein Thrombosis Occurring More Than One Year After LS","Efficacy of Apixaban in Treating Portal Vein Thrombosis Occurring More Than One Year After Laparoscopic Splenectomy","Inclusion Criteria:\n\n1. A clinical, radiological, or histologic diagnosis of cirrhosis of any etiology.\n2. Splenomegaly with secondary hypersplenism.\n3. No evidence of portal vein thrombosis by ultrasound evaluation and angio-CT prior to surgery.\n4. Underwent laparoscopic splenectomy at our center.\n5. Orally received 2.5 mg of apixaban (CTTQ, Nanjing, China) twice daily or a 100 mg aspirin tablet (Bayer, Leverkusen, Germany) once daily for 6 months from POD 3.\n6. subcutaneous injections of low molecular weight heparin sodium (CSBio, Hebei, China) were administered for 5 days from POD 3\n7. Oral dipyridamole (Henan Furen, Henan, China) at a dosage of 25 mg, administered three times daily for 3 months from POD 3.\n8. Had no imaging evidence (Doppler ultrasound or CT) of portal vein thrombosis during postoperative months 6 to 12.\n9. Developed portal vein thrombosis after 12 months post-surgery.\n10. Provided informed consent to participate in the study.\n\nExclusion Criteria:\n\n1. Hepatocellular carcinoma or any other malignancy.\n2. Hypercoagulable state other than the liver disease related.\n3. DRUGS- oral contraceptives, anticoagulation or anti-platelet drugs.\n4. Portal hypertension bleeding .\n5. Child - Pugh C\n6. Recent peptic ulcer disease\n7. History of Hemorrhagic stroke\n8. Pregnancy.\n9. Uncontrolled Hypertension\n10. Human immunodeficiency virus (HIV) infection",{"count":128,"type":21},20,[24],"The purpose of this study is to determine whether Apixaban is effective and safe in the treatment of portal vein thrombosis Occurring more than one year after laparoscopic splenectomy.",[92,132,27,133],"Splenectomy","Hypertension, Portal",[92,27,59,135,132,136],"Apixaban","Laparoscopy","2026-03-25",{"date":139,"type":34},"2026-03-31",{"date":115,"type":21},{"date":142,"type":21},"2027-09-30",{"name":144,"class":41},"Northern Jiangsu People's Hospital",{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":152,"targetDuration":4,"studyType":22,"phases":153,"briefSummary":154,"conditions":155,"keywords":156,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":159,"startDateStruct":160,"completionDateStruct":161,"leadSponsor":162,"locationsCount":42},"100628430","efficacy-of-apixaban-in-treating-portal-vein-thrombosis-occurring-more-than-one-year-after-lsd-100628430","NCT07461532","Efficacy of Apixaban in Treating Portal Vein Thrombosis Occurring More Than One Year After LSD","Efficacy of Apixaban in Treating Portal Vein Thrombosis Occurring More Than One Year After Laparoscopic Splenectomy and Azygoportal Disconnection","Inclusion Criteria:\n\n1. A clinical, radiological, or histologic diagnosis of cirrhosis of any etiology.\n2. Portal hypertension bleeding .\n3. Splenomegaly with secondary hypersplenism.\n4. No evidence of portal vein thrombosis by ultrasound evaluation and angio-CT prior to surgery.\n5. Underwent laparoscopic splenectomy at our center.\n6. Orally received 2.5 mg of apixaban (CTTQ, Nanjing, China) twice daily or a 100 mg aspirin tablet (Bayer, Leverkusen, Germany) once daily for 6 months from POD 3.\n7. subcutaneous injections of low molecular weight heparin sodium (CSBio, Hebei, China) were administered for 5 days from POD 3\n8. Oral dipyridamole (Henan Furen, Henan, China) at a dosage of 25 mg, administered three times daily for 3 months from POD 3.\n9. Had no imaging evidence (Doppler ultrasound or CT) of portal vein thrombosis during postoperative months 6 to 12.\n10. Developed portal vein thrombosis after 12 months post-surgery.\n11. Provided informed consent to participate in the study.\n\nExclusion Criteria:\n\n1. Hepatocellular carcinoma or any other malignancy.\n2. Hypercoagulable state other than the liver disease related.\n3. DRUGS- oral contraceptives, anticoagulation or anti-platelet drugs.\n4. Child - Pugh C\n5. Recent peptic ulcer disease\n6. History of Hemorrhagic stroke\n7. Pregnancy.\n8. Uncontrolled Hypertension\n9. Human immunodeficiency virus (HIV) infection",{"count":128,"type":21},[24],"The purpose of this study is to determine whether Apixaban is effective and safe in the treatment of portal vein thrombosis Occurring more than one year after laparoscopic splenectomy and azygoportal disconnection.",[92,132,27,133],[92,27,59,135,132,136,157,158],"Hypersplenism","Azygoportal disconnection",{"date":139,"type":34},{"date":115,"type":21},{"date":142,"type":21},{"name":144,"class":41},{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":4,"eligibilityCriteria":169,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":170,"enrollmentInfo":171,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":173,"conditions":174,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":42},"100629338","indicators-affecting-pvt-recanalization-100629338","NCT07473375","Indicators Affecting PVT Recanalization","Indicators Affecting Portal Vein Thrombosis Recanalization in Cirrhosis With Gastroesophageal Varices","Inclusion Criteria:\n\n* diagnosed as cirrhosis and confirmed gastroesophageal varices by endoscopy;\n\n  * all patients were diagnosed as PVT by CTA at admission.\n\nExclusion Criteria:\n\n* patients with hepatocellular carcinoma;\n\n  * patients with extrahepatic malignancies;\n\n    * history of liver transplantation or TIPS;\n\n      * lack of information regarding anticoagulation therapy；\n\n        * those with cavernous transformation of the portal vein(CTPV) .","80 Years",{"count":172,"type":21},1500,"This is a retrospective-prospective study conducted at Zhongshan Hospital, Fudan University, to explore portal vein thrombosis (PVT) in patients with cirrhosis and gastroesophageal varices (GEV). It aimed to provide insights into the diagnosis, follow-up, and factors influencing PVT recanalization, to help patients, families, and healthcare providers understand the disease and related clinical management.",[27,92,175,176],"Portal Hypertension Related to Cirrhosis","Portal Hypertension, Noncirrhotic","2026-03-13",{"date":179,"type":34},"2026-03-16",{"date":181,"type":34},"2017-01-01",{"date":183,"type":21},"2028-12-31",{"name":40,"class":41},{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":189,"acronym":190,"eligibilityCriteria":191,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":192,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":194,"conditions":195,"keywords":196,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":209},"100625443","portal-vein-thrombosis-in-cirrhosis-incidence-outcomes-and-anticoagulation-100625443","NCT07422701","Portal Vein Thrombosis in Cirrhosis: Incidence, Outcomes and Anticoagulation","PORTAL","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Clinically or histologically confirmed liver cirrhosis (any etiology)\n* Contrast-enhanced abdominal ultrasound, CT, or MRI performed within 3 months before enrollment to document presence or absence of portal vein thrombosis (PVT)\n* Complete baseline clinical, laboratory, and imaging data available\n* Complete baseline clinical, laboratory, and imaging data available\n* Able and willing to provide written informed consent and comply with 24-month follow-up\n\nExclusion Criteria:\n\n* Concomitant malignant tumor, including hepatocellular carcinoma\n* Previous transjugular intrahepatic portosystemic shunt (TIPS), splenectomy, or liver transplantation\n* Major surgery or severe trauma within 6 months prior to enrollment\n* Pregnancy or breastfeeding\n* Known hereditary thrombophilia or active systemic inflammatory disease\n* Inability or unwillingness to participate in scheduled follow-up (e.g., cognitive impairment, residence far from study sites)",{"count":193,"type":21},2522,"Portal vein thrombosis (PVT) is a blood-clot complication that occurs in some people with liver cirrhosis and can worsen bleeding, ascites, encephalopathy and survival. However, doctors still lack reliable tools to predict who will develop PVT, how much it really shortens life, and whether anticoagulation (blood-thinner) treatment clearly improves outcomes and is safe.This multicentre, bidirectional cohort study will follow about 2,500 adults with cirrhosis cared for at seven major hospitals in China. The team will first review 1,682 historical cases recorded since 2010 and then prospectively enrol another 840 patients from June 2025 onward. Participants may or may not already have PVT when they enter the study. All will undergo routine blood tests and abdominal imaging, and will be followed at roughly 6 months, 1 year and 2 years after discharge, through clinic visits, hospital records or telephone calls.\n\nThe study has three goals :\n\n1. Identify risk factors for new PVT and build an easy-to-use prediction model.\n2. Clarify the impact of PVT on prognosis, especially all-cause death and decompensation of cirrhosis.\n3. Evaluate real-world anticoagulation: patients who receive blood-thinners will be compared with those who do not, looking at survival, clot progression or resolution, and major bleeding events.\n\nBecause no experimental drug or random assignment is involved, participation does not change a patient's routine care. All personal information will be de-identified and protected according to Chinese data-security laws. Results from this study are expected to help doctors recognise high-risk patients earlier and choose safer, more effective anticoagulation strategies to improve quality of life and survival in cirrhosis.",[27,58],[27,58,197,66,198,199],"Risk Factors","Anticoagulation Therapy","Bidirectional Cohort Study","2026-02-13",{"date":202,"type":34},"2026-02-20",{"date":204,"type":21},"2026-02-01",{"date":206,"type":21},"2028-12",{"name":208,"class":41},"Peking University First Hospital",7,{"id":211,"slug":212,"hasResults":11,"nctId":213,"briefTitle":214,"officialTitle":214,"acronym":4,"eligibilityCriteria":215,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":216,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":218,"conditions":219,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":42},"100555568","a-study-of-the-correlation-between-portal-vein-thrombosis-and-prognosis-of-liver-transplantation-100555568","NCT06513780","A Study of the Correlation Between Portal Vein Thrombosis and Prognosis of Liver Transplantation","Inclusion Criteria:\n\n1. Liver transplantation recipients\n2. Aged 18 years or older.\n\nExclusion Criteria:\n\n1. Retransplantation\n2. Multi-organ transplantation\n3. Portal vein tumor thrombus",{"count":217,"type":21},700,"The goal of this observational study is to investigate the correlation between portal vein thrombosis (PVT) and the prognosis of liver transplantation. The main questions it aims to address are:\n\nWhat is the prevalence of PVT? What are the risk factors associated with PVT? What is the prognostic impact of preoperative PVT on liver transplantation?\n\nParticipants are divided into two groups: the PVT group and the non-PVT group. The investigators will comparatively analyze the data of both groups, estimate the prevalence and risk factors of PVT, construct a predictive model for PVT that is applicable in clinical settings, and clarify the prognostic effects of PVT.",[27],"2025-09-15",{"date":222,"type":34},"2025-09-18",{"date":224,"type":34},"2016-01-01",{"date":226,"type":21},"2025-12-31",{"name":228,"class":41},"Ru-zhou Cai",{"id":230,"slug":231,"hasResults":11,"nctId":232,"briefTitle":233,"officialTitle":234,"acronym":4,"eligibilityCriteria":235,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":236,"enrollmentInfo":237,"targetDuration":4,"studyType":22,"phases":239,"briefSummary":240,"conditions":241,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":250,"locationsCount":42},"100603130","phase-4-efficacy--safety-of-anticoagulants-in-cirrhosis--hcc-100603130","NCT07132515","Efficacy & Safety of Anticoagulants in Cirrhosis ± HCC","Efficacy and Safety of Anticoagulant Therapy for Portal Vein Thrombosis In Cirrhosis Patients With and Without Hepatocellular Carcinoma","Inclusion Criteria:\n\n* Portal vein thrombosis, Cirrhosis, With or without HCC, Child A \\& B\n\nExclusion Criteria:\n\n* Platelets\\\u003C10000, Createnine \\>1.9, Budd ciarri, Uncontrolled active bleeding","70 Years",{"count":238,"type":21},100,[89],"We will give an anticoagulant against portal vein thrombosis, and watch for the results.",[92,242,27],"HCC - Hepatocellular Carcinoma","2025-08-17",{"date":245,"type":34},"2025-08-20",{"date":247,"type":34},"2023-08-15",{"date":249,"type":21},"2025-08",{"name":251,"class":41},"Mansoura University",{"id":253,"slug":254,"hasResults":11,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":4,"eligibilityCriteria":258,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":259,"targetDuration":4,"studyType":22,"phases":261,"briefSummary":262,"conditions":263,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":4},"100597730","endoscopic-ultrasound-guided-measurement-of-portal-vein-pressure-gradient-100597730","NCT07062289","Endoscopic Ultrasound-guided Measurement of Portal Vein Pressure Gradient","Study on the Measurement of Portal Vein Pressure Gradient Guided by Endoscopic Ultrasound Based on Portal Vein Thrombosis and Portal Hypertension","Inclusion Criteria:\n\n* Age ≥ 18 years old\n* History of liver cirrhosis\n* INR \\\u003C 1.5\n* Platelet count \\> 50 × 10⁹\u002FL\n* Patients agreed to HVPG and EUS-PPG measurements\n\nExclusion Criteria:\n\n* Patients with ascites\n* Patients with renal insufficiency\n* Patients with active infection\n* Patients with hepatic encephalopathy\n* Critically ill patients\n* Pregnant patients\n* Patients with immunodeficiency diseases (such as systemic lupus erythematosus)\n* Patients with mental illness\n* Patients with malignant tumors\n* Patients who refused to undergo HVPG and EUS-PPG measurements",{"count":260,"type":21},42,[24],"This study aims to evaluate the accuracy and safety of a novel endoscopic ultrasound-guided portal pressure gradient (EUS-PPG) measurement technique in 42 adults with liver cirrhosis and portal vein thrombosis (blood clots in the liver's main vein), a condition where current standard testing (HVPG) fails to provide reliable pressure readings. Participants will undergo both EUS-PPG (using a specialized needle under ultrasound guidance) and HVPG procedures to compare results; EUS-PPG will be performed under general anesthesia in a left-side lying position-an innovative approach-while also enabling immediate endoscopic treatment of bleeding veins if detected during the same session. The primary goals are to validate EUS-PPG's safety in this high-risk group, establish its correlation with HVPG, and pioneer an integrated diagnosis-treatment protocol to reduce hospital stays and costs. The study runs from July 2025 to June 2027 at Zhejiang University School of Medicine.",[27,175],"2025-07-11",{"date":266,"type":34},"2025-07-14",{"date":268,"type":21},"2025-07-01",{"date":270,"type":21},"2027-06-30",{"name":272,"class":41},"Zhejiang University",{"id":274,"slug":275,"hasResults":11,"nctId":276,"briefTitle":277,"officialTitle":278,"acronym":4,"eligibilityCriteria":279,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":236,"enrollmentInfo":280,"targetDuration":4,"studyType":22,"phases":282,"briefSummary":285,"conditions":286,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":287,"lastUpdatePostDateStruct":288,"startDateStruct":290,"completionDateStruct":292,"leadSponsor":294,"locationsCount":42},"100578975","phase-2-compare-the-efficacy-and-safety-of-dabigatran-and-enoxaparin-in-patients-with-portal-vein-thrombosis-with-cirrhosis-100578975","NCT06818279","Compare the Efficacy and Safety of Dabigatran and Enoxaparin in Patients With Portal Vein Thrombosis With Cirrhosis","Compare the Efficacy and Safety of Dabigatran and Enoxaparin in Patients With Portal Vein Thrombosis With Cirrhosis: A Randomized Controlled Study","Inclusion Criteria:\n\n1. Age \\>18 years\n2. Cirrhosis with portal vein thrombosis within 6 months of diagnosis\u002FSymptomatic PVT\u002FPVT in potential transplant recipient.\n\nExclusion Criteria:\n\n1. Contraindications to anticoagulant therapy, such as active bleeding, recent major surgery, or known hypersensitivity to study medications.\n2. CTP \\>10\n3. Hepatocellular carcinoma\n4. Tumoral PVT\n5. Isolated gastric varices with red colour signs\n6. Peptic ulcer disease with large ulcers\n7. Pregnant or breastfeeding women\n8. Thrombocytopenia (platelet count \\\u003C50,000\u002FμL)\n9. Patients with concurrent acute kidney injury or chronic kidney disease stage 4 or 5\n10. Those not giving consent for therapy",{"count":281,"type":21},120,[283,284],"PHASE2","PHASE3","Portal vein thrombosis (PVT) is prevalent among patients with cirrhosis, and its prevalence rises with the severity of liver disease. Numerous studies have indicated that patients developing PVT experience elevated portal pressure and associated complications, such as increased incidence of variceal bleeding, higher rates of failed variceal bleed control, rebleeding, and short-term mortality. Additionally, the development of PVT adversely affects post-transplant outcomes, correlating with increased 30-day mortality among transplant recipients with PVT. Current guidelines lack clarity regarding the optimal choice of anticoagulation therapy for patients with cirrhosis. This study aims to evaluate the efficacy and safety of enoxaparin and dabigatran in achieving complete recanalization of portal vein thrombosis in cirrhotic patients over a 6-month period.",[27,58],"2025-02-04",{"date":289,"type":34},"2025-02-10",{"date":291,"type":21},"2025-01-31",{"date":293,"type":21},"2026-01-31",{"name":295,"class":41},"Institute of Liver and Biliary Sciences, India",{"id":297,"slug":298,"hasResults":11,"nctId":299,"briefTitle":300,"officialTitle":301,"acronym":4,"eligibilityCriteria":302,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":303,"targetDuration":4,"studyType":22,"phases":304,"briefSummary":305,"conditions":306,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":309,"lastUpdatePostDateStruct":310,"startDateStruct":312,"completionDateStruct":314,"leadSponsor":316,"locationsCount":42},"100525516","preemptive-tips-for-variceal-bleeding-in-cirrhotic-patients-with-occlusive-portal-vein-thrombosis-100525516","NCT06122753","Preemptive TIPS for Variceal Bleeding in Cirrhotic Patients With Occlusive Portal Vein Thrombosis","Transjugular Intrahepatic Portosystemic Shunt (TIPS) for Variceal Bleeding in Cirrhotic Patients With Occlusive Portal Vein Thrombosis (PVT): A Multicenter Randomized Trial","Inclusion Criteria:\n\n* Cirrhosis (diagnosed by imaging, laboratory tests, clinical symptoms, or liver biopsy);\n* Admission due to acute bleeding from esophagogastric varices;\n* Thrombus in the main trunk of the portal vein occupying ≥50% of the lumen.\n\nExclusion Criteria:\n\n* Prior treatment with TIPS or surgical shunt;\n* Presence of contraindications to endoscopic treatment, carvedilol, or TIPS;\n* Presence of hepatocellular carcinoma exceeding Milan criteria;\n* Presence of other systemic malignant tumors with expected survival time not exceeding 6 months;\n* Presence of uncontrollable infection or sepsis;\n* Presence of cardiac, pulmonary, or renal failure;\n* Pregnant or lactating women;\n* Refusal to sign the informed consent form.",{"count":281,"type":21},[24],"Portal vein thrombosis (PVT) can lead to a further increase in portal venous pressure and increase the risk of rebleeding. Whether patients with acute esophagogastric variceal bleeding with occlusive PVT benefit from preemptive TIPS is still controversial. The present study is directed at comparing the outcome of patients with acute variceal bleeding with occlusive PVT treated by standard therapy (vasoactive drugs + endoscopic variceal ligation) with or without preemptive TIPS (performed during the first 1-3 days after endoscopic procedure). The primary outcome is survival free of variceal rebleeding at 6 weeks from inclusion.",[59,27,307,308],"Esophageal Varix Bleeding","Portosystemic Shunt","2023-11-03",{"date":311,"type":34},"2023-11-08",{"date":313,"type":21},"2024-01",{"date":315,"type":21},"2026-12",{"name":317,"class":41},"West China Hospital"]